Fulminant Aeromonas hydrophila infection during acute lymphoblastic leukemia treatment. 2012

Vassilios Papadakis, and Nikolaos Poniros, and Karerina Katsibardi, and Athina-Eleni Charissiadou, and John Anastasopoulos, and Sophia Polychronopoulou
Department of Pediatric Hematology- Oncology Aghia Sophia Children's Hospital, Athens, Greece.

Aeromonas hydrophila septicemia has a fulminant course and it has been usually reported in immunocompromised hosts and rarely among children with leukemia. High morbidity and mortality is associated with A hydrophila infections. We describe the case of a child with acute lymphoblastic leukemia who presented with septicemia due to A hydrophila. The patient presented with fever and skin discoloration during a febrile neutropenia episode, which rapidly evolved into bacteremia and extensive thigh suppuration, fasciitis, and myonecrosis. Apart from antibiotic treatment, surgical debridement to relieve compartment pressure and prevent further lower extremity compromise was promptly performed. Despite long delays in chemotherapy and an extensive tissue gap, primary closure of the involved area was possible with full cosmetic and functional limb recovery, and the patient has remained in clinical remission for more than 7 years.

UI MeSH Term Description Entries
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003646 Debridement The removal of foreign material and devitalized or contaminated tissue from or adjacent to a traumatic or infected lesion until surrounding healthy tissue is exposed. (Dorland, 27th ed) Debridements
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D016867 Immunocompromised Host A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation. Immunosuppressed Host,Immunocompromised Patient,Host, Immunocompromised,Host, Immunosuppressed,Hosts, Immunocompromised,Hosts, Immunosuppressed,Immunocompromised Hosts,Immunocompromised Patients,Immunosuppressed Hosts,Patient, Immunocompromised,Patients, Immunocompromised
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D016905 Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method. Bacterial Infections, Gram-Negative,Infections, Gram-Negative Bacterial,Bacterial Infection, Gram-Negative,Gram Negative Bacterial Infections,Gram-Negative Bacterial Infection,Infection, Gram-Negative Bacterial
D016980 Aeromonas hydrophila A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that may be pathogenic for frogs, fish, and mammals, including man. In humans, cellulitis and diarrhea can result from infection with this organism.

Related Publications

Vassilios Papadakis, and Nikolaos Poniros, and Karerina Katsibardi, and Athina-Eleni Charissiadou, and John Anastasopoulos, and Sophia Polychronopoulou
November 1980, Southern medical journal,
Vassilios Papadakis, and Nikolaos Poniros, and Karerina Katsibardi, and Athina-Eleni Charissiadou, and John Anastasopoulos, and Sophia Polychronopoulou
December 2013, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,
Vassilios Papadakis, and Nikolaos Poniros, and Karerina Katsibardi, and Athina-Eleni Charissiadou, and John Anastasopoulos, and Sophia Polychronopoulou
July 2022, Current medical research and opinion,
Vassilios Papadakis, and Nikolaos Poniros, and Karerina Katsibardi, and Athina-Eleni Charissiadou, and John Anastasopoulos, and Sophia Polychronopoulou
December 1980, New York state journal of medicine,
Vassilios Papadakis, and Nikolaos Poniros, and Karerina Katsibardi, and Athina-Eleni Charissiadou, and John Anastasopoulos, and Sophia Polychronopoulou
June 1967, Annals of internal medicine,
Vassilios Papadakis, and Nikolaos Poniros, and Karerina Katsibardi, and Athina-Eleni Charissiadou, and John Anastasopoulos, and Sophia Polychronopoulou
January 1978, JAMA,
Vassilios Papadakis, and Nikolaos Poniros, and Karerina Katsibardi, and Athina-Eleni Charissiadou, and John Anastasopoulos, and Sophia Polychronopoulou
January 1974, Plastic and reconstructive surgery,
Vassilios Papadakis, and Nikolaos Poniros, and Karerina Katsibardi, and Athina-Eleni Charissiadou, and John Anastasopoulos, and Sophia Polychronopoulou
March 1997, Presse medicale (Paris, France : 1983),
Vassilios Papadakis, and Nikolaos Poniros, and Karerina Katsibardi, and Athina-Eleni Charissiadou, and John Anastasopoulos, and Sophia Polychronopoulou
January 1991, The Journal of emergency medicine,
Vassilios Papadakis, and Nikolaos Poniros, and Karerina Katsibardi, and Athina-Eleni Charissiadou, and John Anastasopoulos, and Sophia Polychronopoulou
May 1995, Ugeskrift for laeger,
Copied contents to your clipboard!